4 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 44 points (0.3%) at 15,464 as of Tuesday, Aug. 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,183 issues advancing vs. 1,800 declining with 78 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Osiris Therapeutics ( OSIR), up 112.4%, Novo Nordisk A/S ( NVO), up 0.7% and AstraZeneca ( AZN), up 0.6%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Regeneron Pharmaceuticals is down $3.05 (-1.2%) to $242.91 on light volume. Thus far, 297,421 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 810,200 shares. The stock has ranged in price between $242.02-$245.96 after having opened the day at $245.59 as compared to the previous trading day's close of $245.96.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $24.2 billion and is part of the health care sector. Shares are up 43.8% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Allergan ( AGN) is down $0.81 (-0.9%) to $90.26 on average volume. Thus far, 1.6 million shares of Allergan exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $89.48-$91.26 after having opened the day at $91.07 as compared to the previous trading day's close of $91.07.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.1 billion and is part of the health care sector. Shares are down 0.7% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Amgen ( AMGN) is down $0.39 (-0.4%) to $107.82 on light volume. Thus far, 1.1 million shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $107.03-$108.81 after having opened the day at $108.63 as compared to the previous trading day's close of $108.21.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $82.6 billion and is part of the health care sector. Shares are up 27.2% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is down $2.83 (-2.0%) to $138.00 on average volume. Thus far, 1.5 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $136.74-$141.20 after having opened the day at $141.03 as compared to the previous trading day's close of $140.83.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $58.4 billion and is part of the health care sector. Shares are up 81.1% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing